Patents by Inventor Daisuke Wakamatsu

Daisuke Wakamatsu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230034441
    Abstract: A pump unit and a pump capable of detecting characteristics of a conveyance article and a method for detecting the characteristics of the conveyance article. A pump unit includes an outer cylinder; an inner cylinder disposed on an inner circumference side of the outer cylinder; and a pressure supply chamber provided between the inner cylinder and the outer cylinder, the pump unit being configured to convey a conveyance article in the inner cylinder by supplying a pressurizing medium into the pressure supply chamber and thereby causing the inner cylinder to expand inwardly in a radial direction, in which the pump unit further includes a conveyance article information acquiring device configured to acquire information on the conveyance article in the inner cylinder at a time when the inner cylinder is expanded.
    Type: Application
    Filed: December 16, 2020
    Publication date: February 2, 2023
    Applicant: CHUO UNIVERSITY
    Inventors: Taro NAKAMURA, Yasuyuki YAMADA, Kota WAKAMATSU, Daiki HAGIWARA, Haruka ADACHI, Daisuke MATSUI
  • Patent number: 10676438
    Abstract: The present invention relates to a compound represented by the general formula (I) (wherein the definition of each group has the same meaning as described in the specification). The compound is useful as preventive and/or therapeutic agent for KCNQ2-5 channel-related diseases.
    Type: Grant
    Filed: August 9, 2018
    Date of Patent: June 9, 2020
    Assignee: Ono Pharmaceutical Co., Ltd.
    Inventors: Kentaro Yashiro, Daisuke Wakamatsu, Tetsuji Saito
  • Publication number: 20200157050
    Abstract: The present invention relates to a compound represented by the general formula (I) (wherein the definition of each group has the same meaning as described in the specification). The compound is useful as preventive and/or therapeutic agent for KCNQ2-5 channel-related diseases.
    Type: Application
    Filed: January 24, 2020
    Publication date: May 21, 2020
    Applicant: Ono Pharmaceutical Co., Ltd.
    Inventors: Kentaro YASHIRO, Daisuke WAKAMATSU, Tetsuji SAITO
  • Patent number: 10570093
    Abstract: The present invention relates to a compound represented by the general formula (I) (wherein the definition of each group has the same meaning as described in the specification). The compound is useful as preventive and/or therapeutic agent for KCNQ2-5 channel-related diseases.
    Type: Grant
    Filed: August 9, 2018
    Date of Patent: February 25, 2020
    Assignee: Ono Pharmaceutical Co., Ltd.
    Inventors: Kentaro Yashiro, Daisuke Wakamatsu, Tetsuji Saito
  • Patent number: 10519105
    Abstract: An object of the present invention is to provide a novel compound having a strong opening action with respect to KCNQ2-5 channels. A compound represented by the general formula (I) (wherein the definition of each group is as described in the specification) is provided. The compound represented by the general formula (I) has a strong opening action with respect to KCNQ2-5 channels, and therefore is useful as a prophylactic and/or therapeutic agent for a KCNQ2-5 channel-related disease (for example, dysuria, overactive bladder, or the like).
    Type: Grant
    Filed: April 21, 2017
    Date of Patent: December 31, 2019
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Kentaro Yashiro, Masashi Kato, Tetsuji Saito, Takuya Okada, Daisuke Wakamatsu, Adam James Davenport, Christopher Charles Stimson
  • Publication number: 20190135755
    Abstract: Crystal polymorphism may exist in a crystalline compound. In the case where crystal polymorphism exists, depending on the crystal form, solubility, dissolution rate, stability against heat, light, humidity, etc. or the like is different. Accordingly, in the production of a pharmaceutical product, it is a very important task to select a crystal form of a drug substance most suitable for a disease indication and a dosage form. The present invention relates to novel crystal forms (A crystal, W crystal, and a hydrate crystal (H crystal)) of a compound I having a strong opening action with respect to KCNQ2-5 channels.
    Type: Application
    Filed: April 21, 2017
    Publication date: May 9, 2019
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Kentaro YASHIRO, Hideomi KIJIMA, Daisuke WAKAMATSU, Tetsuji SAITO
  • Publication number: 20190127320
    Abstract: An object of the present invention is to provide a novel compound having a strong opening action with respect to KCNQ2-5 channels. A compound represented by the general formula (1) (wherein the definition of each group is as described in the specification) is provided. The compound represented by the general formula (1) has a strong opening action with respect to KCNQ2-5 channels, and therefore is useful as a prophylactic and/or therapeutic agent for a KCNQ2-5 channel-related disease (for example, dysuria, overactive bladder, or the like).
    Type: Application
    Filed: April 21, 2017
    Publication date: May 2, 2019
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Kentaro YASHIRO, Masashi KATO, Tetsuji SAITO, Takuya OKADA, Daisuke WAKAMATSU, Adam James DAVENPORT, Christopher Charles STIMSON
  • Patent number: 10196358
    Abstract: The present invention relates to a compound represented by the general formula (I) (wherein the definition of each group has the same meaning as described in the specification). The compound is useful as preventive and/or therapeutic agent for KCNQ2-5 channel-related diseases.
    Type: Grant
    Filed: August 8, 2017
    Date of Patent: February 5, 2019
    Assignee: Ono Pharmaceutical Co., Ltd.
    Inventors: Kentaro Yashiro, Daisuke Wakamatsu, Tetsuji Saito
  • Publication number: 20180346422
    Abstract: The present invention relates to a compound represented by the general formula (I) (wherein the definition of each group has the same meaning as described in the specification). The compound is useful as preventive and/or therapeutic agent for KCNQ2-5 channel-related diseases.
    Type: Application
    Filed: August 9, 2018
    Publication date: December 6, 2018
    Applicant: Ono Pharmaceutical Co., Ltd.
    Inventors: Kentaro Yashiro, Daisuke WAKAMATSU, Tetsuji SAITO
  • Publication number: 20170334855
    Abstract: The present invention relates to a compound represented by the general formula (I) (wherein the definition of each group has the same meaning as described in the specification). The compound is useful as preventive and/or therapeutic agent for KCNQ2-5 channel-related diseases.
    Type: Application
    Filed: August 8, 2017
    Publication date: November 23, 2017
    Applicant: Ono Pharmaceutical Co., Ltd.
    Inventors: Kentaro Yashiro, Daisuke Wakamatsu, Tetsuji Saito
  • Patent number: 9809544
    Abstract: The present invention relates to a compound, 1-[(5-chloro-2-pyridinyl)methyl]-3-{2,6-dichloro-4-[(2S)-1,1,1-trifluoro-2-hydroxy-2-propanyl]phenyl}urea, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: October 23, 2015
    Date of Patent: November 7, 2017
    Assignee: Ono Pharmaceutical Co., Ltd.
    Inventors: Kentaro Yashiro, Daisuke Wakamatsu, Tetsuji Saito
  • Publication number: 20170217888
    Abstract: The present invention relates to a compound represented by the general formula (I) (wherein the definition of each group has the same meaning as described in the specification). The compound is useful as preventive and/or therapeutic agent for KCNQ2-5 channel-related diseases.
    Type: Application
    Filed: October 23, 2015
    Publication date: August 3, 2017
    Applicant: Ono Pharmaceutical Co., Ltd
    Inventors: Kentaro YASHIRO, Daisuke WAKAMATSU, Tetsuji SAITO
  • Publication number: 20090226412
    Abstract: The present invention relates to a hemorrhage reducing agent in cerebrovascular disorder containing a poly (ADP-ribose) polymerase inhibitor (PARP inhibitor). The PARP inhibitor provides an inhibitory effect of vascular endothelial cell disorder so that it may reduce hemorrhage in cerebrovascular disorder. In addition, the PARP inhibitor inhibits the hemorrhage that is concerned about in thrombolytic agent use by using together with a thrombolytic agent, and an effect of extending therapeutic time window of a thrombolytic agent may be further expected. Furthermore, the PARP inhibitor can be a safe hemorrhage reducing agent with fewer side effects because it does not affect the blood coagulation system and the fibrinolytic system.
    Type: Application
    Filed: June 23, 2006
    Publication date: September 10, 2009
    Applicant: ONO PHARMACEUTICAL CO., LTD.,
    Inventors: Tetsuya Yasuhiro, Takashi Kitajima, Daisuke Wakamatsu, Wataru Kamoshima
  • Patent number: 6926915
    Abstract: The present invention provides a method for selective and high-yield separation, concentration, and recovery of desired cells from a blood sample.
    Type: Grant
    Filed: March 30, 2000
    Date of Patent: August 9, 2005
    Assignee: Netech, Inc.
    Inventors: Hirofumi Yura, Yoshio Saito, Michihiro Kitagawa, Daisuke Wakamatsu, Akira Ihara
  • Publication number: 20050042354
    Abstract: It is intended to obtain highly active and fat-soluble antiradicals originating in a natural substance whereby the stability of foods (fat compositions) can be elevated and disorders caused by oxidation in vivo can be prevented simultaneously. Namely (1) an antiradical containing 4-vinyl-2,6-dimethoxyphenol as the active ingredient; (2) an antiradical comprising an extract of crude rapeseed oil containing 4-vinyl-2,6-dimethoxyphenol; (3) a crude rapeseed oil extract containing 4-vinyl-2,6-dimethoxyphenol in a concentrated state characterized by being prepared by treating crude rapeseed oil with an alcohol or an aqueous alcohol or distilling it; and (4) an antiradical containing these three types of crude rapeseed oil extracts.
    Type: Application
    Filed: October 9, 2002
    Publication date: February 24, 2005
    Inventors: Shigeru Morimura, Kenji Kida, Hiroshi Maeda, Fumi Yasuda, Daisuke Wakamatsu, Jun Tsunehiro, Chiaki Nakai
  • Publication number: 20050032201
    Abstract: The present invention provides a method for selective and high-yield separation, concentration, and recovery of desired cells from a blood sample.
    Type: Application
    Filed: September 9, 2004
    Publication date: February 10, 2005
    Applicant: NETECH INC.
    Inventors: Hirofumi Yura, Yoshio Saito, Michihiro Kitagawa, Daisuke Wakamatsu, Akira Ihara